Pyrazino [1'2':1,6 ] pyrido [3, 4-b] indole-1,4-dione...

Details Pyrazino [1'2':1,6 ] pyrido [3, 4-b] indole-1,4-dione... Pyrazino [1'2':1,6 ] pyrido [3, 4-b] indole-1,4-dione...

2006-08-29

2006-08-29

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S342000, C544S343000

Reexamination Certificate

active

07098209

ABSTRACT:
Compounds of the general structural formula (I), and use of the compounds and salts and solvates thereof, as thereapeutic agents. In particular, the invention relates to compounds that are potent and selective inhibitors of cyclic guanosine 3′, 5′-monophosphate specific phosphodiesterase (cGMP-specific PDE), in particular PDE5, and have utility in a variety of therapeutic areas wherein such inhibition is considered beneficial, including the treatment of cardiovascular disorders and erectile dysfunction

REFERENCES:
patent: 57-11984 (1982-01-01), None
patent: WO 95/19978 (1995-07-01), None
Cialis ® Prescribing Information, Eli Lilly and Company, Indianapolis, IN 46282, U.S.A. (2003).
Karsten et al, “Involvement of cyclic nucleosides in renal artery smooth muscle relaxation” Urology Research, vol. 30, pp. 367-373 (2003).
Fritz et al, “Stimulation of the Nitric Oxide-Guanosine 3',5'-Cyclic Monophosphate Pathway by Sildenafil: Effect on Rectal Muscle Tone, Distensibility, and Perception in Health and in Irritable Bowel Syndrome” Am. J. Gastroenterology, vol. 98(10), pp. 2253-2260, (2003).
Kaplan et al, “Safety and Efficacy of Sildenafil in Postmenopausal Women with Sexual Dysfunction” Urology, vol. 53(3), pp. 481-486 (1999).
Berman, M.D. and Goldstein, M.D. Letters to the Editor, Urology, vol. 54(3), pp. 578-579, (1999).
Word and Cornwell, “Regulation of cGMP-induced relaxation and cGMP-dependent protein kinase in rat myometrium during pregnancy” Am. J. Physiol. 274 (Cell Physiol. 43), pp. C748-C756, (1998).
Perry and Higgs, “Chemotherapeutic potential of phosphodiesterase inhibitors” Current Opinion in Chemical Biology, vol. 2, pp. 472-481 (1998).
Willette et al, “Identification, Characterization, and Functional Role of Phosphodiesterase Type IV in Cerebral Vessels: Effects of Selective Phosphodiesterse Inhibitors” J. Cerebral Blood Flow and Metabolism, vol. 17, pp. 210-219 (1997).
Sybertz and Czarnieki, “Inhibitors of PDE1 and PDE5 cGMP phosphodiesterases: patents and therapeutic potential” Expert Opinion on Therapeutic Patents, vol. 7(6), pp. 631-639 (1997).
McDonald et al, “2,7-Dioxo-2,3,4,5,6,7-hexahydro-1H-benzo[h][1,4]diazinone as a New Template for the Design of CCK2 Receptor Antagonists” J. Med. Chem., vol. 43, pp. 3518-3529 (2000).

Affiliated with

Also associated with

Rating

Pyrazino [1'2':1,6 ] pyrido [3, 4-b] indole-1,4-dione... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrazino [1'2':1,6 ] pyrido [3, 4-b] indole-1,4-dione..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazino [1'2':1,6 ] pyrido [3, 4-b] indole-1,4-dione... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3635471